Dr. Shu is a co-founder of Argo Biopharma. Before Argo, Dr. Shu served as a senior scientist at Arrowhead Pharmaceuticals, where he focused on developing extrahepatic delivery platforms, some of which are successfully applied in clinical studies. Prior to Arrowhead, Dr. Shu conducted his postdoctoral research at Northwestern University. Dr. Shu received his Ph.D. in chemistry from the University of Wisconsin-Madison, and his B.S. from Peking University.

Dr. Shao is a co-founder of Argo Biopharma with over two decades of experience in drug research and development. Prior to his role at Argo, he led research and development at Mitotherapeutix, a startup specializing in siRNA-based new drug discovery for treating NASH. Preceding this, he held the position of Director of Medicinal Chemistry at Arrowhead Pharmaceuticals, leading efforts in extrahepatic delivery platforms and programs. His journey in drug discovery began at Merck Research Labs, where he served as a principal scientist involved in various projects spanning cardiovascular health, diabetes, oncology, and CNS disorders. Dr. Shao earned his Ph.D. in chemistry from University of Victoria and conducted postdoctoral research in natural product synthesis at University of Rochester.

Dr. Xia is a co-founder of Argo Biopharma with a compound background in academia, industry and investment. Dr. Xia once served as the product director of Heyi Gene, a domestic genetic diagnostic company, the investment director of Hangzhou Medical Port Operation Company, and the investment director of Future Capital. Dr. Xia obtained his Ph.D. in biochemistry and molecular biology from Peking University, and postdoctoral fellow at Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine.

Dr. Jin received his M.D. and Ph.D. from Shanghai Medical College, Fudan University. With 18 years of experience in MNC, he has played a leading role in Clinical Development and Medical Affairs at Wyeth, BI, and Lilly China. He also served as the Head of Clinical Development at Novartis China, where he successfully led the team in conducting the Asia Phase 3 study of siRNA drug LEQVIO^® (inclisiran). Dr. Jin has extensive knowledge in various therapeutic areas including immunology, CNS, cardiovascular/metabolism, kidney disease, bone, infection, respiratory, ophthalmology, hematology, and oncology. Prior to joining Argo, he held the position of CMO at a domestic siRNA biotech company and was an operating partner at a healthcare investment firm. During his time there, he successfully incubated and established a renal biotech in China.